IL-10 and glucocorticoids inhibit Aβ(1-42) and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system

Journal of Alzheimer's Disease

Volumn 5, Issue 2, 2003, Pages 105-117

  Szczepanik, Ann Marie ^a   Ringheim, Garth E ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CHEMOKINE; CYTOKINE; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRUCTURE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NEUROPIL; NEUROTOXICITY; NONHUMAN; PAIRED HELICAL FILAMENT; PRIORITY JOURNAL;

EID: 0038291979     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2003-5205     Document Type: Article

References (58)

1. C.R. Abraham, D.J. Selkoe and H. Potter, Immunochemical identification of the serine protease inhibitor alantichymotrypsin in the brain amyloid deposits of Alzheimer's disease, Cell 52 (1988), 487-501.
2. A. Afagh, B.J. Cummings, D.H. Cribbs, C.W. Cotman and A.J. Tenner, Localization and cell association of C1q in Alzheimer's disease brain, Exp. Neurol. 138 (1996), 22-32.
3. P.S. Aisen, D. Marin, L. Alstiel, C. Goodwin, B. Baruch, R. Jacobson, T. Ryan and K.L. Davis, A pilot study of prednisone in Alzheimer's disease, Dementia 7 (1996), 201-206.
4. P.S. Aisen, K.L. Davis, J.D. Berg, K. Schafer, K. Campbell, R.G Thomas, M.F. Weiner, M.R. Farlow, M. Sano, M. Grundman and L.J. Thal, A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study, Neurology 54 (2000), 588-593.
5. D.M. Araujo and C.W. Cotman, β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease, Brain Res. 569 (1992), 141-145.
6. K. Asadullah, W.D. Docke, M. Ebeling, M. Friedrich, G. Belbe, H. Audring, H.D. Volk and W. Sterry, Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial, Arch. Dermatol. 135 (1999), 187-192.
7. J. Bauer, S. Strauss, U. Schreiter-Gasser, U. Ganter, P. Schlegel, I. Witt, B. Yolk and M. Berger, Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices, FEBS Lett. 285 (1991), 111-114.
8. W.C. Benzing, J.R. Wujek, E.K. Ward, D. Shaffer, K.H. Ashe, S.G. Younkin and K.R. Brunden, Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice, Neurobiol. Aging 20 (1999), 581-589.
9. H. Bessler, C. Mendel, R. Straussberg, N. Gurary, D. Aloni and L. Sirota, Effects of dexamethasone on IL-1β, IL-6, and TNF-α production by mononuclear cells of newborns and adults, Biol. Neonate 75 (1999), 225-233.
10. J.C. Breitner, B.A. Gau, K.A. Welsh, B.L. Plassman, W.M. McDonald, M.J. Helms and J.C. Anthony, Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study, Neurology 44 (1994), 227-232.
11. J.C.S. Breitner, K.A. Welsh, M.J. Helms, P.C. Gaskell, B.A. Gau, A.D. Roses, M.A. Perciak-Vance and A.M. Saunders, Delayed onset of Alzheimer's disease with nonsteriodal anti-inflammatory and histamine H2 blocking drugs, Neurobiol. Aging 16 (1995), 523-530.
12. R. Cacabelos, X.A. Alvarez, L. Fernández-Novoa, A. Franco, R. Mangues, A. Pellicer and T. Nishimura, Brain interleukin-1 beta in Alzheimer's disease and vascular dementia, Methods Findings Exp. Clin. Pharmacol. 16 (1994), 141-151.
13. B.L. Dean, C. Lee, J.E. Kirsch, V.M. Runge, R.M. Dempsey and L.C. Pettigrew, Cerebral hemodynamics and cerebral blood volume: MR assessment using adolinium contrast agents and T1-weighted Turbo-FLASH imaging, Amer. J. Neuroradiology 13 (1992), 39-48.
14. R.H. DeRijk, M. Schaaf and E.R. de-Kloet, Glucocorticoid receptor variants: clinical implications, J. Steroid Biochem. and Mol. Biol. 81 (2002), 103-122.
15. D.W. Dickson, S.C. Lee, L.A. Mattiace, S.H. Yen and C. Brosnan, Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease, Glia 7 (1993), 75-83.
16. P.E. Duffy, M. Rapport and L. Graf, Glial fibrillary acidic protein and Alzheimer-type senile dementia, Neurology 30 (1980), 778-782.
17. H. Fillit, W. Ding, L. Buee, J. Kalman, L. Altstiel, B. Lawlor and G. Wolf-Klein, Elevated circulating tumor necrosis factor levels in Alzheimer's disease, Neurosci. Lett. 129 (1991), 318-320.
18. G. Forloni, F. Mangiarotti, N. Angeretti, E. Lucca and M.G. DeSimoni, β-amyloid fragment potentiates IL-6 and TNF-alpha secretion by LPS in astrocytes but not in microglia, Cytokine 9 (1997), 759-762.
19. D. Franchimont, H. Martens, M.T. Hagelstein, E. Louis, W. Dewe, G.P. Chrousos, J. Belaiche and V. Geenen, Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor, J. Clin. Endocrinol. Metab. 84 (1999), 2834-2839.
20. B.D. Gitter, L.M. Cox, R.E. Rydel and P.C. May, Amyloid beta peptided potentiates cytokine secretion by interleukin-1beta-activated human astrocytoma cells, Proc. Natl. Acad. Sci. USA 92 (1995), 10738-10741.
21. E. Goujon, S. Layé, P. Parnet and R. Dantzer, Regulation of cytokine gene expression in the central nervous system by glucocorticoids: mechanisms and functional consequences, Psychoneuroendocrinology, 22 (1997), S75-80.
22. W.S.T. Griffin, L.C. Stanley, C. Ling, L. White, V. MacLeod, L.J. Perrot, C.L. White III and C. Araoz, Brain interleukin1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease, Proc. Natl. Acad. Sci. USA 86 (1989), 7611-7615.
23. W.S.T. Griffin, J.G. Sheng and R.E. Mrak, Inflammatory pathways: Implications in Alzheimer's disease, in: Molecular Mechanisms of Dementia, W. Wasco and R.E. Tanzi, eds, Humana Press, Inc., New Jersey, 1997, pp. 169-176.
24. B. Hauss-Wegrzyniak, P. Dobrzanski, J.D. Stoehr and G.L. Wenk, Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease, Brain Res. 780 (1998), 294-303.
25. M. Huell, S. Strauss, B. Volk, M. Berger and J. Bauer, Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients, Acta Neuropathologica 89 (1995), 544-551.
26. K. Ishizuka, T. Kimura, R. Igata-yi, S. Katsuragi, L. Takamatsu and T. Mikakawa, Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease, Psychiatry Clin. Neurosci. 51 (1997), 135-138.
27. S. Itagaki, H. Akiyama, H. Saito and P.L. McGeer, Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease, Brain Res. 645 (1994), 78-84.
28. A.S. Lanzrein, C.M. Johnson, V.H. Perry, K.A. Jobst, E.M. King and A.D. Smith, Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin, Alzheimer Dis. Assoc. Disord. Disease and Associated Disorders 12 (1998), 215-227.
29. G.P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O. Ubeda, K.H. Ashe, S.A. Frautschy and G.M. Cole, Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease, J. Neurosci. 20 (2000), 5709-5714.
30. E.G. McGeer and P.L. McGeer, Brain inflammation in Alzheimer disease and the therapeutic implications, Curr. Pharm. Design 5 (1999), 821-836.
31. P.L. McGeer, S. Itagaki, H. Tago and E.G. McGeer, Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR, Neurosci. Lett. 79 (1987), 195-200.
32. P.L. McGeer, M. Schulzer and E.G. McGeer, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies, Neurology 47 (1996), 425-432.
33. L. Meda, M.A. Cassatella, G.I. Szendrei, L. Otvos, Jr., P. Baron, M. Villalba, D. Ferrari and F. Rossi, Activation of microglial cells by β-amyloid protein and interferon-γ, Nature 374 (1995), 647-650.
34. L. Meda, S. Bernasconi, C. Bonaiuto, S. Sozzani, D. Zhou, L. Otvos, Jr., A. Mantovani, F. Rossi and M.A. Cassatella, β-amyloid (25-35) peptide and IFN-γ synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells, J. Immunol. 157 (1996), 1213-1218.
35. G. Mehlhorn, M. Hollborn and R. Schliebs, Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology, Int. J. Dev. Neurosci. 18 (2000), 423-431.
36. Y. Natori, Y. Natori, T. Nishimura, H. Yamabe, K. Iyonaga, M. Takeya and M. Kawakami, Production of monocyte chemoattractant protein-1 by cultured glomerular epithelial cells: inhibiton by dexamethasone, Exp. Nephrol. 5 (1997), 318-322.
37. D.R. Nelson, G.Y. Lauwers, J.Y. Lau and G.L. Davis, Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders, Gastroenterology 118 (2000), 655-660.
38. E.E. Netland, J.L. Newton, R.E. Majocha, and B.A. Tate, Indomethacin reverses the microglial response to amyloid β-protein, Neurobiol. Aging 19 (1998), 210-204.
39. R. Paganelli, A. Di Ioio, L. Patricelli, F. Ripani, E. Sparvieri, R. Faricelli, C. Iarlori, E. Porreca, M. Di Gioacchino and G. Abate, Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients, Exp. Gerontology 37 (2002), 257-263.
40. C.M. Pariante, B.D. Pearce, T.L. Pisell, C.I. Sanchez, C. Po, C. Su and A.H. Miller, The proinflammatory cytokine, IL-1α, reduces glucocorticoid receptor translocation and function, Endocrinology 140 (1999), 4359-4366.
41. X. Qiao, D.J Cummins and S.M. Paul, Neuroinflammationinduced acceleration of amyloid deposition in the APPV717F transgenic mouse, Eur. J. Neurosci 14 (2001), 474-482.
42. D. Refojo, A.C. Liberman, F. Holsboer and E. Arzt, Transcription factor-mediated molecular mechanisms involved in the functional cross-talk between cytokines and glucocorticoids, Immunol. Cell Biol. 79 (2001), 385-394.
43. J. Rogers, L.C. Kirby, S.R. Hempelman, D.L. Berry, P.L. McGeer, A.W. Kaszniak, J. Zalinski, M. Cofield, L. Mansukhani, P. Willson and F. Kogan, Clinical trial of indomethacin in Alzheimer's disease, Neurology 43 (1993), 1609-1611.
44. H. Sakurai, N. Shigemori, Y. Hisada, T. Ishizuka, K. Kawashima and T. Sugita, Suppression of NF-κB and AP-1 activation by glucocorticoids in experimental glomerulonephritis in rats: molecular mechanisms of anti-nephritic action, Biochim. Biophys. Acta. 1362 (1997), 252-262.
45. O. Salinero, M.T. Moreno-Flores and F. Wandosell, Okadaic acid modulates the cytoskeleton changes induced by amyloid peptide (25-35) in cultured astrocytes, Neuroreport 8 (1997), 3333-3338.
46. O. Salinero, M.T. Moreno-Flores, M.L. Ceballos and F. Wandosell, β-Amyloid peptide induced cytoskeletal reorganization in cultured astrocytes, J. Neurosci. Res. 47 (1997), 216-223.
47. C. Scali, C. Prosperi, L. Giovannelli, L. Bianchi, G. Pepeu, and F. Casamenti, β(1-40) Amyloid peptide injection into the nucleus basalis of rats induces microglia reaction and enhances cortical γ-aminobutyric acid release in vivo, Brain Res. 831 (1999), 319-321.
48. D.J. Selkoe, Alzheimer's disease: a central role for amyloid, J. Neuropathol. Exp. Neurol. 53 (1994), 438-447.
49. J.G. Sheng, R.E. Mrak and W.S. Griffin, Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution, Neuropath. Appl. Neurobiol. 21 (1995), 290-301.
50. H.A. Smits, A.J. van Beelen, N.M de Vos, A. Rijsmus, T. van der Bruggen, J. Verhoef, F.L van Muiswinkel and H.S. Nottet, Activation of human macrophages by amyloid-beta is attenuated by astrocytes, J. Immunol. 166 (2001), 6869-6876.
51. D.K. Song, M.H. Won, J.S. Jung, J.C. Lee, T.C. Kang, H.W. Suh, S.O. Huh, S.H. Paek, Y.H. Kim, S.H. Kim and Y.H. Suh, Behavioral and neuropathological changes induced by central injection of carboxyl-terminal fragment of β-amyloid precursor protein in mice, J. Neurochem. 71 (1998), 875-878.
52. A.M. Szczepanik, S. Funes, W. Petko and G.E. Ringheim, IL-4, IL-10 and IL-1β modulate Aβ(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line, J. Neuroimmunol. 113 (2001), 49-62.
53. A.M. Szczepanik, D. Rampe and G.E. Ringheim, Amyloidβ peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo, J. Neurochem. 76 (2001), 1-15.
54. S.J. van Deventer, C.O. Elson and R.N. Fedorak, Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group, Gastroenterology 113 (1997), 383-389.
55. J.A. van Roon, J.L. van Roy, F.H. Gmelig-Meyling, F.P. Lafeber and J.W. Bijlsma, Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4, Arthritis Rheum. 39 (1996), 829-835.
56. D.T. Weldon, S.D. Rogers, J.R. Ghilardi, M.P. Finke, J.P. Cleary, E. O'Hare, W.P. Esler, J.E. Maggio and P.W. Mantyh, Fibrillar β-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo, J. Neurosci. 18 (1998), 2161-2173.
57. J.A. Wood, P.L. Wood, R. Ryan, N.R. Graff-Radford, C. Pilapil, Y. Robitaille and R. Quirion, Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-RA but increases in the associated acute phase proteins IL6, α2-macroglobulin and C-reactive protein, Brain Res. 629 (1993), 245-252.
58. G.S. Zubenko, Molecular neurobiology of Alzheimer's disease (Syndrome?), Harv. Rev. Psychiatry 5 (1997), 177-213.